ArticleInfectious diseases of poverty2020
Progress on the national echinococcosis control programme in China: analysis of humans and dogs population intervention during 2004-2014.
Article in Infectious diseases of poverty, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Alveolar Echinococcosis in the Early 2020s: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- Spatio-temporal dynamics, trend analysis, and incidence prediction of echinococcosis in Xinjiang, China (2005-2024).BMC public health · 2026Article
- Five-Year Slaughterhouse-Based Surveillance ofPathogens (Basel, Switzerland) · 2025Article
- Spatiotemporal distribution and control of echinococcosis in Xinjiang, 2005-2023.PLoS neglected tropical diseases · 2025Article
- Optimization of echinococcosis control measures based on system dynamics.PLoS computational biology · 2025Article
- Analysis and prediction of the incidence temporal trends of echinococcosis in China from 2010 to 2021.Scientific reports · 2025Article
- Development and protective efficacy of multi-epitope vaccine FL46 against cystic echinococcosis.Frontiers in immunology · 2025Article
- A new case ofFrontiers in cellular and infection microbiology · 2025Article
- Dynamical variations, impact factors, and prediction of echinoco-ccosis in Xinjiang by ARIMA-Random Forest Hybrid Model.PloS one · 2025Article
- Analysis of risk factors and a clinical prediction model for human cerebral echinococcosis in Ganzi region, China.Brain communications · 2025Article
- Epidemiology and Clinical Characteristics of Cerebral Alveolar Echinococcosis in the Tibetan Region of Sichuan, China.The American journal of tropical medicine and hygiene · 2024Article
- Epidemiological characteristics and risk factors for cystic and alveolar echinococcosis in China: an analysis of a national population-based field survey.Parasites & vectors · 2023Article
- The Impact of Environmental and Host Factors on Human Cystic Echinococcosis: A County-Level Modeling Study in Western China.GeoHealth · 2023Article
- Prevalence of Intestinal Parasites in Dog Faecal Samples from Public Environments in Qinghai Province, China.Pathogens (Basel, Switzerland) · 2022Article
- The impact of environmental factors on human echinococcosis epidemics: spatial modelling and risk prediction.Parasites & vectors · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA national control program for echinococcosis has been in effect since 2005 in China. This program has applied a comprehensive strategy, and good control results have been achieved. Human echinococcosis prevalence rate decrease from 1.08% in 2004 to 0.24% in 2012. The objective of this study is focusing on assessment of the programme with two indices, including patient treatment and registered dogs deworming, in endemic areas of echincoccosis control over the period of 10 years (2004-2014) in China.
methodsWe established the database including demography at county and township levels with coverage for ten provinces and autonomous regions of China in this study. We using methods of epidemiological descriptive, instead the expectation-maximization for missing value filling for grouping available patients into those subjected to surgery and those receiving drug treatment after population screening and the dogs population after registered by deworming. We performed Microsoft Excel software and SPSS software on the results as percentages with the corresponding 95% confidence intervals (95% CIs). We also statistically analyzed the economics data on patient treatment and dogs deworming after the corresponding discount with annual bank interest rates (USD 1 = CNY 6.5, bank discount average changes of 2.3-3.3%).
resultsDuring 2004-2014, the grant total average rate of surgical patient (after surgical operation) treatment had increased with 32.4% and with 81.3% for medical treatment with albendazole. Meanwhile, it increased by 58.6% for the deworming of registered dog since 2007. The accumulated costs amounted to USD 27.03 million after discount for patients and registered dog treatment, which is 1/4 of the total accumulated financial inputs (USD 110.67 million from the Chinese Government). Since the implementation of the national program, it has increased 57 times with respect to the annual financial inputs (costs) and 368 times with respect to all accumulated financial inputs (costs).
conclusionsThis study showed that in endemic areas, patient diagnosis and management, dog management and treatment over this period helped reduce the parasite load to control the disease. More attention should be paid to controlling wild canines during the ongoing program period and sustainable follow-up evaluations are crucial for success and continued implementation of the national program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.